Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/115259
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSteinberg, Julia-
dc.contributor.authorGizaw, Muluken-
dc.contributor.author[und viele weitere]-
dc.date.accessioned2024-03-08T13:52:06Z-
dc.date.available2024-03-08T13:52:06Z-
dc.date.issued2024-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/117214-
dc.identifier.urihttp://dx.doi.org/10.25673/115259-
dc.description.abstractWhile previous reviews found a positive association between pre-existing cancer diagnosis and COVID-19-related death, most early studies did not distinguish long-term cancer survivors from those recently diagnosed/treated, nor adjust for important confounders including age. We aimed to consolidate higher-quality evidence on risk of COVID-19-related death for people with recent/active cancer (compared to people without) in the pre-COVID-19-vaccination period. We searched the WHO COVID-19 Global Research Database (20 December 2021), and Medline and Embase (10 May 2023). We included studies adjusting for age and sex, and providing details of cancer status. Risk-of-bias assessment was based on the Newcastle-Ottawa Scale. Pooled adjusted odds or risk ratios (aORs, aRRs) or hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were calculated using generic inverse-variance random-effects models. Random-effects meta-regressions were used to assess associations between effect estimates and time since cancer diagnosis/treatment. Of 23 773 unique title/abstract records, 39 studies were eligible for inclusion (2 low, 17 moderate, 20 high risk of bias). Risk of COVID-19-related death was higher for people with active or recently diagnosed/treated cancer (general population: aOR = 1.48, 95% CI: 1.36-1.61, I2 = 0; people with COVID-19: aOR = 1.58, 95% CI: 1.41-1.77, I2 = 0.58; inpatients with COVID-19: aOR = 1.66, 95% CI: 1.34-2.06, I2 = 0.98). Risks were more elevated for lung (general population: aOR = 3.4, 95% CI: 2.4-4.7) and hematological cancers (general population: aOR = 2.13, 95% CI: 1.68-2.68, I2 = 0.43), and for metastatic cancers. Meta-regression suggested risk of COVID-19-related death decreased with time since diagnosis/treatment, for example, for any/solid cancers, fitted aOR = 1.55 (95% CI: 1.37-1.75) at 1 year and aOR = 0.98 (95% CI: 0.80-1.20) at 5 years post-cancer diagnosis/treatment. In conclusion, before COVID-19-vaccination, risk of COVID-19-related death was higher for people with recent cancer, with risk depending on cancer type and time since diagnosis/treatment.eng
dc.language.isoeng-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.ddc610-
dc.titleRisk of COVID-19 death for people with a pre-existing cancer diagnosis prior to COVID-19-vaccination : a systematic review and meta-analysiseng
dc.typeArticle-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleInternational journal of cancer-
local.bibliographicCitation.volume154-
local.bibliographicCitation.issue8-
local.bibliographicCitation.pagestart1394-
local.bibliographicCitation.pageend1412-
local.bibliographicCitation.publishernameWiley-Liss-
local.bibliographicCitation.publisherplaceBognor Regis-
local.bibliographicCitation.doi10.1002/ijc.34798-
local.openaccesstrue-
dc.identifier.ppn1882944747-
cbs.publication.displayform2024-
local.bibliographicCitation.year2024-
cbs.sru.importDate2024-03-08T13:51:11Z-
local.bibliographicCitationEnthalten in International journal of cancer - Bognor Regis : Wiley-Liss, 1966-
local.accessrights.dnbfree-
Appears in Collections:Open Access Publikationen der MLU